NYSE:Acceleron Pharma Inc.
График котировок Acceleron Pharma Inc.
График XLRN предоставлен TradingView
Добавить в список сравнения
Добавить в список отслеживания
Добавить в портфель
Основные параметры
P/S | 71.56 |
---|---|
P/BV | 8.44 |
EV/EBITDA | -50.57 |
EBITDA | -0.13 |
Цена ао | 125.88 |
Инсайдерская торговля
Дата сделки | Дата раскрытия | Инсайдер | Тип | Цена | Объем | Количество | Доля до, % | Доля после, % | Документ |
---|---|---|---|---|---|---|---|---|---|
11.12.2020 | 11.12.2020 | MCLAUGHLIN KEVIN F SVP, CFO and Treasurer |
Продажа | 125 | 387 500.00 | 3100 | 0 | -0.01 | ссылка |
09.12.2020 | 11.12.2020 | MCLAUGHLIN KEVIN F SVP, CFO and Treasurer |
Продажа | 125.03 | 484 116.00 | 3872 | 0 | -0.01 | ссылка |
10.12.2020 | 11.12.2020 | MCLAUGHLIN KEVIN F SVP, CFO and Treasurer |
Продажа | 125.12 | 62 560.00 | 500 | 0 | 0 | ссылка |
Основные владельцы
Institutions | Объем | Доля, % |
---|---|---|
Hennion & Walsh, Inc | 200 | 0 |
Foresite Capital Management III, LLC | 108630 | 0.18 |
Peroni Portfolio Advisors, Inc | 300 | 0 |
Putnam Investment Management, LLC | 381471 | 0.63 |
Fidelity Management & Research Company LLC | 3487318 | 5.79 |
First Trust Portfolios L.P. | 10365 | 0.02 |
Columbia Wanger Asset Management LLC | 541172 | 0.9 |
Baron Capital Management Inc | 845643 | 1.4 |
Principal Global Investors, LLC | 227853 | 0.38 |
Fidelity SelectCo, LLC | 2635961 | 4.37 |
Granahan Investment Management Inc | 91177 | 0.15 |
Kennedy Capital Management | 41541 | 0.07 |
Westend Sa | 1400000 | 2.32 |
AXA Investment Managers UK Ltd | 207067 | 0.34 |
Invesco Capital Management LLC | 67344 | 0.11 |
Zeus Asset Management S.A. | 1253 | 0 |
Artal Group S A | 1400000 | 2.32 |
BlackRock Fund Advisors | 1270397 | 2.11 |
Artisan Partners Holdings LP | 531970 | 0.88 |
Prudential Retirement Services | 174917 | 0.29 |
PMG Fonds Management AG | 17200 | 0.03 |
Содержится в ETF
ETF | Доля, % | Доходность за год, % |
---|---|---|
First Trust BuyWrite Income ETF | 2.73 | |
First Trust Hedged BuyWrite Income ETF | 2.64 |
Похожие компании
Описание Acceleron Pharma Inc.
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.